Kexing Biopharm Co., Ltd. (SHA:688136)
China · Delayed Price · Currency is CNY 30.16
+1.40 (4.87%)
At close: Mar 6, 2026
Kexing Biopharm Market Cap
Kexing Biopharm has a market cap or net worth of 5.97 billion as of March 6, 2026. Its market cap has increased by 62.09% in one year.
Market Cap
5.97B
Enterprise Value
6.76B
Revenue
1.54B
Ranking
n/a
PE Ratio
37.23
Stock Price
30.16
Market Cap Chart
Since December 14, 2020, Kexing Biopharm's market cap has decreased from 8.15B to 5.97B, a decrease of -26.68%. That is a compound annual growth rate of -5.76%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 6, 2026 | 5.97B | -4.77% |
| Dec 31, 2025 | 6.27B | 45.13% |
| Dec 31, 2024 | 4.32B | 7.17% |
| Dec 29, 2023 | 4.03B | -5.31% |
| Dec 30, 2022 | 4.26B | -24.16% |
| Dec 31, 2021 | 5.62B | -30.78% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 14, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Beijing Konruns Pharmaceutical | 6.34B |
| R&G PharmaStudies | 6.31B |
| Lifecome Biochemistry | 6.23B |
| Xiangxue Pharmaceutical | 6.22B |
| GemPharmatech | 6.05B |
| Shanghai OPM Biosciences | 5.92B |
| Novogene | 5.75B |
| Shouyao Holdings (Beijing) Co., LTD. | 5.55B |